We propose to continue the extraordinarily successful Global Alliance in Pharmacogenomics- Japan (GAP-J) as a network resource for the Pharmacogenomics Research Network (PGRN). GAP-J (see Figure XII.1) is an existing alliance (see http://vwvw.nigms.nih.gov/lnitiatives/PGRN/GAP/) between the PGRN and the Center for Genomic Medicine (CGM) of the Riken, Yokohama Institute in Japan (see www.src.riken.ip/english/for description of CGM). This international alliance brings together scientists in multiple research disciplines to conduct research in pharmacogenomics. In particular, the research focuses on genomewide association studies to identify genetic predictors of therapeutic and adverse reactions to medicines. GAP-J was started after initial discussions between Dr. Yusuke Nakamura, Director of the CGM and Drs. Mark Ratain and Kathy Giacomini, Principal Investigators in the PGRN. The discussions centered on the need to expedite discoveries in pharmacogenomics so that personalized medicines could be realized. A partnership between the PGRN, which would contribute rich sets of well-phenotyped samples and the CGM, which would contribute powerful high throughput genomewide methods, was discussed. Formal launching of GAP-J occurred in the Spring of 2008 with a letter of intent signed by Dr. Yusuke Nakamura, Director of the Center for Genome Medicine, Riken;Dr. Scott Weiss, Chair, Pharmacogenefics Research Network;and NIH Institute Directors, Drs. Jeremy Berg (National Institute of General Medical Sciences), John Niederhuber (National Cancer Institute) and Elizabeth Nabel (National Heart, Lung and Blood Institute). Currently fourteen research collaborations focused on genomewide association analysis of many drug response phenotypes are underway in GAP-J (see Table XII.1).

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-GGG-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Ryu, Ann H; Eckalbar, Walter L; Kreimer, Anat et al. (2017) Use antibiotics in cell culture with caution: genome-wide identification of antibiotic-induced changes in gene expression and regulation. Sci Rep 7:7533
Chhibber, A; French, C E; Yee, S W et al. (2017) Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines. Pharmacogenomics J 17:137-145
Stecula, Adrian; Schlessinger, Avner; Giacomini, Kathleen M et al. (2017) Human Concentrative Nucleoside Transporter 3 (hCNT3, SLC28A3) Forms a Cyclic Homotrimer. Biochemistry 56:3475-3483
Wu, Hsin-Fang; Hristeva, Nadya; Chang, Jae et al. (2017) Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. J Pharm Sci 106:2751-2757
Wheeler, Heather E; Gamazon, Eric R; Frisina, Robert D et al. (2017) Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. Clin Cancer Res 23:3325-3333
Sá, Ana Caroline C; Webb, Amy; Gong, Yan et al. (2017) Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. Sci Rep 7:16068
Eclov, Rachel J; Kim, Mee J; Smith, Robin P et al. (2017) In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus. Drug Metab Dispos 45:208-215
Dujic, T; Zhou, K; Yee, S W et al. (2017) Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis. Clin Pharmacol Ther 101:763-772
Zhou, Kaixin; Yee, Sook Wah; Seiser, Eric L et al. (2016) Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 48:1055-1059
Mitchel, Katrina; Theusch, Elizabeth; Cubitt, Celia et al. (2016) RP1-13D10.2 Is a Novel Modulator of Statin-Induced Changes in Cholesterol. Circ Cardiovasc Genet 9:223-30

Showing the most recent 10 out of 148 publications